Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies

Inflammatory vaginitis occurs at similar rates in women with multiple sclerosis on B-cell depleting therapy and those on other disease-modifying therapies

S Conway, C Dodson, G Hui, CW Pike, K Galetta

Multiple Sclerosis and Related Disorders, 92: 105921 (2024)

Plain-language summary

We examined whether women with multiple sclerosis taking B-cell-depleting therapies (treatments that reduce certain immune cells) had higher rates of inflammatory vaginitis compared to those on other disease-modifying treatments. By reviewing medical records from 2015 to 2023, we found similar rates of vaginitis in both groups, indicating no strong link to B-cell therapy. The condition was common across all patients, highlighting the need for better understanding and management of inflammatory vaginitis in women with multiple sclerosis.

Abstract

This study investigates the occurrence of inflammatory vaginitis in women with Multiple Sclerosis (wwMS) undergoing B-cell depleting therapy versus other disease-modifying therapies (DMTs). Retrospective analysis of medical records from Stanford University between 2015-2023 shows similar rates of vaginitis in both groups, suggesting no significant association with B-cell therapy. Despite this, inflammatory vaginitis remains prevalent in both treatment groups, warranting further investigation into its mechanisms and management.

Details

Publication Type
Comparative Study
Journal
Multiple Sclerosis and Related Disorders
Date Published
October 17, 2024
Volume
92
Pages
105921
Digital Object Identifier
10.1016/j.msard.2024.105921
PubMed Identifier
39454471

Document Preview

Open PDF